Current status of blood 'pharming': Megakaryoctye transfusions as a source of platelets
Current opinion in hematology, 2017•journals.lww.com
This present review will describe the present state-of-the-art in generating and delivering
nondonor-derived platelets. Progress has been slow, but advances in our ability to generate
human megakaryocytes in culture, generate PLPs from these cells, and test the functionality
of the resultant platelets in vitro and in vivo have identified important remaining challenges
and raised alternative potential solutions.
nondonor-derived platelets. Progress has been slow, but advances in our ability to generate
human megakaryocytes in culture, generate PLPs from these cells, and test the functionality
of the resultant platelets in vitro and in vivo have identified important remaining challenges
and raised alternative potential solutions.
Summary
This present review will describe the present state-of-the-art in generating and delivering nondonor-derived platelets. Progress has been slow, but advances in our ability to generate human megakaryocytes in culture, generate PLPs from these cells, and test the functionality of the resultant platelets in vitro and in vivo have identified important remaining challenges and raised alternative potential solutions.
Lippincott Williams & Wilkins